Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long‐wavelength ultraviolet light

Lin, Lily; Hanson, Carl V.; Alter, Harvey J.; Jauvin, Valérie; Bernard, Kristen A.; Murthy, Krishna K.; Metzel, Peyton; Corash, Laurence

doi:10.1111/j.0041-1132.2005.04316.x

Cited by 160 publications

(177 citation statements)

References 56 publications

Supporting

Mentioning

171

Contrasting

Unclassified

Order By: Relevance

“…This was done with photochemical treatment by Amotosalem and UVA, a technology that is efficient against the vast majority of known pathogens and which might also prevent the transmission of unknown pathogens (25,(38)(39)(40)(41) INTERCEPT technology is routinely used for PI of PLTs and plasma for clinical use as it is able to inactivate a wide spectrum of bacteria, viruses, and parasites, as well as contaminating leukocytes (42)(43)(44)(45)(46). INTERCEPT process and nucleic acids targeting PI technology is not, however, effective against prion diseases, therefore the risk of prion transmission by treated lysates would remain.…”

Section: Discussionmentioning

confidence: 99%

Inactivated human platelet lysate with psoralen: a new perspective for mesenchymal stromal cell production in Good Manufacturing Practice conditions

et al. 2014

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Inactivated human platelet lysate with psoralen: a new perspective for mesenchymal stromal cell production in Good Manufacturing Practice conditions

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Detailed haemovigilance and post marketing surveillance in Europe since 2003 continues to demonstrate safety and efficacy of the treated products. [54][55][56][57][58] Although high levels of inactivation have been demonstrated for a number of viruses including single-stranded RNA viruses, 38,40 the efficacy of amotosalen and UVA treatment of inactivation of high CHIKV doses had not been tested. Here, we describe the successful inactivation of high doses of CHIKV in apheresis platelet concentrates and plasma components using the amotosalen and UVA treatment process.…”

Section: Introductionmentioning

confidence: 99%

Photochemical Inactivation of Chikungunya Virus in Human Apheresis Platelet Components by Amotosalen and UVA Light

Tsetsarkin¹,

Sampson‐Johannes²,

Sawyer³

et al. 2013

The American Society of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

Abstract. Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that recently re-emerged in Africa and rapidly spread into countries of the Indian Ocean basin and South-East Asia. The mean viremic blood donation risk for CHIKV on La Réunion reached 1.5% at the height of the 2005-2006 outbreaks, highlighting the need for development of safety measures to prevent transfusion-transmitted infections. We describe successful inactivation of CHIKV in human platelets and plasma using photochemical treatment with amotosalen and long wavelength UVA illumination. Platelet components in additive solution and plasma units were inoculated with two different strains of high titer CHIKV stock (6.0-8.0 logs/mL), and then treated with amotosalen and exposure to 1.0-3.0 J/cm 2 UVA. Based on in vitro assays of infectious virus pre-and post-treatment to identify endpoint dilutions where virus was not detectable, mean viral titers could effectively be reduced by 6.4 ± 0.6 log 10 TCID 50 /mL in platelets and 7.6 ± 1.4 logs in plasma, indicating this treatment has the capacity to prevent CHIKV transmission in human blood components collected from infected donors in or traveling from areas of CHIKV transmission.

show abstract

“…In the Intercept system, amotosalen binds nonspecifically to the double stranded region of DNA and RNA of pathogens, and when exposed to ultraviolet light, it forms permanent cross-links to the nucleic acid strands, thus blocking DNA/RNA replication [16]. The system has been shown to inactivate enveloped viruses (HIV, HBV, HCV and west Nile virus) [17], Gram negative and Gram positive bacteria, and protozoa [18].…”

Section: Pathogen Reduction Technologymentioning

confidence: 99%

Modern banking, collection, compatibility testing and storage of blood and blood components

2014

View full text Add to dashboard Cite

SummaryThe clinical practice of blood transfusion has changed considerably over the last few decades. The potential risk of transfusion transmissible diseases has directed efforts towards the production of safe and high quality blood. All transfusion services now operate in an environment of ever‐increasing regulatory controls encompassing all aspects of blood collection, processing and storage. Stringent donor selection, identification of pathogens that can be transmitted through blood, and development of technologies that can enhance the quality of blood, have all led to a substantial reduction in potential risks and complications associated with blood transfusion. In this article, we will discuss the current standards required for the manufacture of blood, starting from blood collection, through processing and on to storage.

show abstract

Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long‐wavelength ultraviolet light

Abstract: PCT inactivates a broad spectrum of pathogenic, blood-borne viruses. Inactivation of viruses in PLT concentrates with amotosalen and UVA offers the potential to prospectively prevent the majority of PLT transfusion-associated viral diseases.

Cited by 160 publications

References 56 publications

Inactivated human platelet lysate with psoralen: a new perspective for mesenchymal stromal cell production in Good Manufacturing Practice conditions

Inactivated human platelet lysate with psoralen: a new perspective for mesenchymal stromal cell production in Good Manufacturing Practice conditions

Photochemical Inactivation of Chikungunya Virus in Human Apheresis Platelet Components by Amotosalen and UVA Light

Modern banking, collection, compatibility testing and storage of blood and blood components

Contact Info

Product

Resources

About